Concepedia

Efficacy Exposure-response Analysis

Efficacy Exposure-Response Analysis is a systematic pharmacometric approach that characterizes the relationship between the magnitude of drug exposure and the therapeutic effect of interest, distinguishing itself by focusing explicitly on quantifying the extent and variability of beneficial clinical outcomes across different exposure levels.

57

Publications

2.5K

Citations

493

Authors

239

Institutions

Publications per year

2017–2026

38

Parents

Publications

57

Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia

Karen Thudium Mueller, Edward Waldron, Stephan A. Grupp et al. · Clinical Cancer Research · 2018 · 222 citations · Full text

, , +17

Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial

Michael Untch, Richard D. Gelber, Christian Jackisch et al. · Annals of Oncology · 2008 · 197 citations

, , +13

Association of Time‐Varying Clearance of Nivolumab With Disease Dynamics and Its Implications on Exposure Response Analysis

C Liu, Jiajie Yu, H Li et al. · Clinical Pharmacology & Therapeutics · 2017 · 189 citations

, , +17

Results From the IQ‐CSRC Prospective Study Support Replacement of the Thorough QT Study by QT Assessment in the Early Clinical Phase

Börje Darpö, Charles Benson, Corina Dota et al. · Clinical Pharmacology & Therapeutics · 2015 · 180 citations · Full text

, , +14

Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase

Richard A. Larson, Ophelia Yin, Andreas Hochhaus et al. · European Journal of Clinical Pharmacology · 2011 · 107 citations · Full text

, , +12

1–5 of 57

Authors

493

  1. JT
    Josep Tabernero

    Vall d'Hebron Hospital Universitari, Spain

    3 publications · 91 citations

    3

    h-index

  2. EV
    Eric Van Cutsem

    KU Leuven, Belgium

    3 publications · 91 citations

    3

    h-index

  3. DF
    David Ferry

    Eli Lilly (United States), United States

    3 publications · 91 citations

    3

    h-index

  4. MH
    Michael Heathman

    Eli Lilly (United States), United States

    3 publications · 85 citations

    3

    h-index

  5. GB
    G. Bodoky

    Unified Szent István and Szent László Hospital, Hungary

    3 publications · 91 citations

    3

    h-index

1–5 of 493

Institutions

239

  1. Pfizer (United States)

    New York, United States

    7 h-index

    24 publications

    852 citations

  2. Eli Lilly (United States)

    Indianapolis, United States

    6 h-index

    23 publications

    724 citations

  3. Novartis (United States)

    New York, United States

    6 h-index

    19 publications

    2.5K citations

  4. Charité - Universitätsmedizin Berlin

    Berlin, Germany

    5 h-index

    5 publications

    478 citations

  5. Novartis (Switzerland)

    Basel, Switzerland

    5 h-index

    11 publications

    1.2K citations

  6. AbbVie (United States)

    North Chicago, United States

    5 h-index

    28 publications

    675 citations

  7. Certara (United States)

    St Louis, United States

    4 h-index

    6 publications

    272 citations

  8. National Cancer Center Hospital East

    Kashiwa, Japan

    4 h-index

    4 publications

    107 citations

1–8 of 239

Venues

  1. Clinical Pharmacology & Therapeutics

    CPT · 9 publications · 583 citations

    9

    h-index

  2. The Journal of Clinical Pharmacology

    6 publications · 102 citations

    6

    h-index

  3. Cancer Chemotherapy and Pharmacology

    6 publications · 113 citations

    6

    h-index

  4. Molecular Cancer Therapeutics

    MCT · 2 publications · 82 citations

    2

    h-index

  5. Clinical Pharmacokinetics

    2 publications · 66 citations

    2

    h-index

1–5